CHMP recommends Xydalba (dalbavancin) for ABSSSI- Durata Therapeutics/Actavis
On 18 December 2014, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product Xydalba (dalbavancin) from Durata Therapeutics/Actavis, 500mg, powder for concentrate for solution for infusion intended for treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI) in adults.The active substance of Xydalba is dalbavancin, a glycopeptide antibacterial (J01XA04), which interrupts cell wall synthesis in susceptible Gram-positive bacteria.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.